DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cardura (Doxazosin Mesylate) - Published Studies

 
 



Cardura Related Published Studies

Well-designed clinical trials related to Cardura (Doxazosin)

Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. [2014]

Long-term effects of doxazosin, finasteride, and combination therapy on quality of life in men with benign prostatic hyperplasia. [2013]

Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. [2013]

Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. [2011.09]

Tamsulosin and doxazosin as adjunctive therapy following shock-wave lithotripsy of renal calculi: randomized controlled trial. [2011.08.12]

An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. [2011.07]

[Kidney-tonifying and dampness-expelling Chinese herbal medicine combined with doxazosin for the treatment of chronic epididymitis]. [2010.12]

[Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS]. [2010.09]

Preliminary study of efficacy of doxazosin as a medical expulsive therapy of distal ureteric stones in a randomized clinical trial. [2010.06]

A double-blind, crossover study of Doxazosin and Enalapril on peripheral vascular tone and nocturnal blood pressure in sleep apnea patients. [2010.03]

Effectiveness of doxazosin in treatment of distal ureteral stones in children. [2009.12]

Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. [2009.08]

Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. [2009.03]

Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. [2008.09]

Effect of Vardenafil on Blood Pressure Profile of Patients With Erectile Dysfunction Concomitantly Treated With Doxazosin Gastrointestinal Therapeutic System for Benign Prostatic Hyperplasia. [2008.07.16]

Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination. [2008]

The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia. [2007.11]

Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. [2007.10]

Doxazosin for the management of distal-ureteral stones. [2007.05]

Differential effects of urapidil and doxazosin on heart rate. [2007.03]

LC-MS determination and relative bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers. [2007.02.19]

Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. [2007.02]

Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. [2007]

Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. [2006.11]

A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. [2006.10]

[One-year controlled therapy with doxazosin in patients with pulmonary hypertension due to chronic obstructive pulmonary disease] [2006.05]

Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure. [2006.03]

Controlled-release doxazosin as combination therapy in hypertension: the GATES study. [2006.03]

Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients. [2006.02]

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. [2006.01]

Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. [2006]

Bioequivalence evaluation of two formulations of doxazosin tablet in healthy thai male volunteers. [2005.12]

Hemodynamic effects of alpha1-adrenoceptor antagonist, doxazosin, in patients with chronic congestive heart failure. [2005.10]

Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. [2005.10]

A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia. [2005.09]

Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension. [2005.06]

Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. [2005.06]

Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. [2005.06]

Doxazosin GITS versus standard doxazosin in mild to moderate hypertension. [2005.05.11]

Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. [2005.01]

Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. [2004.11]

Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. [2004.04]

Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. [2004.03]

Relationship between body mass index and anti-hypertensive efficacy of doxazosin according to a survey of Japanese patients. [2004.03]

Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. [2004.03]

[Doxazosin in the gastrointestinal therapeutic system (GITS) formulation and trial without catheter after acute urinary retention due to BPH. Dose increase action on recovery effect] [2004.01]

Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. [2004.01]

Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. [2004]

[Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability] [2000.07.27]

Well-designed clinical trials possibly related to Cardura (Doxazosin)

Initial combined treatment with anticholinergics and alpha-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. [2011.12]

Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. [2011.06]

[Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]. [2011.04]

Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. [2011.04]

Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. [2011.02]

Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. [2011]

[Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia]. [2010.12.01]

Finasteride for benign prostatic hyperplasia. [2010.10.06]

Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). [2009.11.24]

The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia. [2009.11]

Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? [2009.09]

Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study. [2009.06]

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. [2009.05.11]

Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2008.11.25]

Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: the Japan Morning Surge 1 study. [2008.10]

Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. [2008.09]

Orthostatic hypertension detected by self-measured home blood pressure monitoring: a new cardiovascular risk factor for elderly hypertensives. [2008.08]

An alpha-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension: the Japan Morning Surge-1 Study. [2008.06]

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.28]

Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart(R) and Tamsulosin) trial rationale and study design. [2007.11]

Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. [2007.11]

Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. [2007.11]

[Comparison of different drugs on the treatment of benign prostate hyperplasia] [2007.07.15]

Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. [2007.04]

A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). [2007.04]

Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.04]

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. [2007.01]

Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. [2006.10.31]

Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.09]

Anxiety-induced plasma norepinephrine augmentation increases reactive oxygen species formation by monocytes in essential hypertension. [2006.06]

Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2006.05.09]

The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. [2006.05]

Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. [2006.04]

[The comparative study on selective alpha1-blocker and behavioural therapy in the treatment of discoordinated voiding in children] [2006]

Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. [2005.06.28]

The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. [2005.06]

Other research related to Cardura (Doxazosin)

[Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for IIĀ° ? benign prostatic hyperplasia with overactive bladder]. [Article in Chinese] [2013]

The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. [2013]

Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial. [2012]

Tamsulosin and doxazosin as adjunctive therapy following shock-wave lithotripsy of renal calculi: randomized controlled trial. [2012]

Effect of doxazosin on expression of eNOS in rat kidney in the presence of partial bladder outlet obstruction. [2011.12.02]

Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. [2011.11]

Orthostatic hypertension: home blood pressure monitoring for detection and assessment of treatment with doxazosin. [2011.09.15]

Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats. [2011.03]

Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. [2011]

Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. [2011]

pH-independent sustained release matrix tablet containing doxazosin mesylate: effect of citric acid. [2010.12]

Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate. [2010.11.15]

[Clinical efficacy of a short-term regimen of Cardura XL on lower urinary tract symptoms and international prognostic scoring system in the treatment of benign prostatic hyperplasia]. [2010.11.02]

Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. [2010.08]

Interactions of biopolymers carrageenans with cationic drug doxazosin mesylate characterized by means of differential scanning calorimetry. [2010.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014